News >

CAR T-Cell Therapy Brings Hope to Relapsed/Refractory Myeloma

Angelica Welch
Published: Thursday, Sep 20, 2018

Eric L. Smith, MD, PhD
Eric L. Smith, MD, PhD
The advent of cellular therapy has invigorated the field of multiple myeloma, particularly for patients in the relapsed/refractory setting who have historically had a poor prognosis, according to Eric Smith, MD, PhD. However, he said, there is still more to accomplish regarding chimeric antigen receptor (CAR) T-cell therapy.

during the 2018 SOHO Annual Meeting, Smith, a medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discussed the development of novel CAR T-cell therapies for patients with myeloma.

OncLive: What are some of the new developments in CAR T-cell therapy for patients with myeloma that you discussed in your presentation at the 2018 SOHO Annual Meeting?

Smith: One of the most exciting advances in recent times for myeloma has been the advent of cellular therapy. We are seeing responses in patients who really have no other options, and a very limited prognosis. The responses so far to date do not seem durable in the majority of patients. I discussed ways to advance CAR T-cell therapy for myeloma with novel CAR T-cell vectors that may hopefully enhance the depth and persistence of responses to CAR T cells for those patients.

What are some of the products currently in the landscape? Which ones are coming down the pike?

bb2121 is the most advanced in terms of data that have been presented in the relapsed population and are being treated in US-based clinical trials. I have been involved in the development of JCARH125, which is also progressing in clinical trials now. The results have not been reported.

Other things that we are looking at for the next generation of CAR T-cell therapies include targeting more than 1 target with the same CAR vector. Also, at MSK, we have pioneered what we call "armored CAR T cells." There, we have done gene modification to the T cell, not only encoding for the CAR, but also for a second gene that encodes a protein, which gives the T cells a further advantage to eradicate the myeloma in the immunosuppressive microenvironment.

You mentioned persistence of CAR T cells. Could you explain what the challenge is there?

Multiple studies with CD19 and BCMA CAR T cells for myeloma have shown that the expansion and persistence of the gene-modified T cells correlate with deeper and more durable responses. There are a few reasons now why patients are relapsing after CAR T-cell therapy. One of which is because the target antigen gets downregulated or is not expressed in a small population of cells, and those cells end up growing out. For that reason, we are looking at dual targeting.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication